# | Title | Journal | Year | Citations |
---|
1 | Mutational landscape and significance across 12 major cancer types | Nature | 2013 | 3,695 |
2 | A framework for advancing our understanding of cancer-associated fibroblasts | Nature Reviews Cancer | 2020 | 2,012 |
3 | Renal cell carcinoma | Nature Reviews Disease Primers | 2017 | 1,727 |
4 | Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study | Lancet, The | 2020 | 1,395 |
5 | Proteogenomics connects somatic mutations to signalling in breast cancer | Nature | 2016 | 1,384 |
6 | The Origin and Evolution of Mutations in Acute Myeloid Leukemia | Cell | 2012 | 1,365 |
7 | Macrophages as regulators of tumour immunity and immunotherapy | Nature Reviews Immunology | 2019 | 1,365 |
8 | DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome | Nature | 2008 | 1,275 |
9 | Frequent Mutation of BAP1 in Metastasizing Uveal Melanomas | Science | 2010 | 1,242 |
10 | Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers | Cell | 2012 | 1,038 |
11 | Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma | New England Journal of Medicine | 2021 | 961 |
12 | Whole-genome analysis informs breast cancer response to aromatase inhibition | Nature | 2012 | 922 |
13 | Human T Regulatory Cells Can Use the Perforin Pathway to Cause Autologous Target Cell Death | Immunity | 2004 | 844 |
14 | Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies | Nature Cell Biology | 2006 | 770 |
15 | Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy | Nature Medicine | 2016 | 738 |
16 | Nomenclature of hepatic anatomy and resections: a review of the Brisbane 2000 system | Journal of Hepato-Biliary-Pancreatic Surgery | 2005 | 726 |
17 | Granzyme B and Perforin Are Important for Regulatory T Cell-Mediated Suppression of Tumor Clearance | Immunity | 2007 | 715 |
18 | Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial | Journal of Clinical Oncology | 2018 | 702 |
19 | Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma | Blood | 2009 | 697 |
20 | Multi-platform discovery of haplotype-resolved structural variation in human genomes | Nature Communications | 2019 | 636 |
21 | Integrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma | Cell | 2019 | 629 |
22 | Pathogenic Germline Variants in 10,389 Adult Cancers | Cell | 2018 | 620 |
23 | Increasing Burden of Melanoma in the United States | Journal of Investigative Dermatology | 2009 | 615 |
24 | Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal | Cell | 2018 | 609 |
25 | Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines | Cell Systems | 2018 | 605 |
26 | Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial | Journal of Clinical Oncology | 2017 | 584 |
27 | Outcome Prediction for Estrogen Receptor-Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics | Journal of the National Cancer Institute | 2008 | 566 |
28 | Five-Year Survival After Resection of Hepatic Metastases From Colorectal Cancer in Patients Screened by Positron Emission Tomography With F-18 Fluorodeoxyglucose (FDG-PET) | Annals of Surgery | 2004 | 541 |
29 | Identification of a Titin-Derived HLA-A1–Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3–Directed T Cells | Science Translational Medicine | 2013 | 539 |
30 | Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes | Nature Genetics | 2012 | 513 |
31 | Tissue-Resident Macrophages in Pancreatic Ductal Adenocarcinoma Originate from Embryonic Hematopoiesis and Promote Tumor Progression | Immunity | 2017 | 499 |
32 | Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma | Molecular Therapy | 2017 | 498 |
33 | Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor | Nature | 2015 | 486 |
34 | Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031 | Journal of Clinical Oncology | 2011 | 470 |
35 | CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer | Nature Genetics | 2017 | 460 |
36 | Effect of Steatohepatitis Associated with Irinotecan or Oxaliplatin Pretreatment on Resectability of Hepatic Colorectal Metastases | Journal of the American College of Surgeons | 2005 | 450 |
37 | DGIdb: mining the druggable genome | Nature Methods | 2013 | 443 |
38 | Lymph Node Staging by Positron Emission Tomography in Patients With Carcinoma of the Cervix | Journal of Clinical Oncology | 2001 | 439 |
39 | Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project | Lancet Oncology, The | 2009 | 433 |
40 | Genomic Landscape of Ewing Sarcoma Defines an Aggressive Subtype with Co-Association of STAG2 and TP53 Mutations | Cancer Discovery | 2014 | 418 |
41 | Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma | Cell | 2020 | 410 |
42 | SciClone: Inferring Clonal Architecture and Tracking the Spatial and Temporal Patterns of Tumor Evolution | PLoS Computational Biology | 2014 | 400 |
43 | Acquisition of Murine NK Cell Cytotoxicity Requires the Translation of a Pre-existing Pool of Granzyme B and Perforin mRNAs | Immunity | 2007 | 391 |
44 | The R882H DNMT3A Mutation Associated with AML Dominantly Inhibits Wild-Type DNMT3A by Blocking Its Ability to Form Active Tetramers | Cancer Cell | 2014 | 374 |
45 | Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study | Lancet Oncology, The | 2016 | 373 |
46 | Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: Relationship to therapeutic response—a preliminary report | International Journal of Radiation Oncology Biology Physics | 2003 | 324 |
47 | Impact of Mobilization and Remobilization Strategies on Achieving Sufficient Stem Cell Yields for Autologous Transplantation | Biology of Blood and Marrow Transplantation | 2008 | 319 |
48 | Mechanisms of aromatase inhibitor resistance | Nature Reviews Cancer | 2015 | 319 |
49 | The Physician-Scientist Career Pipeline in 2005 | JAMA - Journal of the American Medical Association | 2005 | 317 |
50 | Risk of malignancy in thyroid incidentalomas identified by fluorodeoxyglucose-positron emission tomography | Surgery | 2001 | 284 |